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OBJECTIVE: To compare pelvic floor muscle training and a sham procedure for the treatment of lower urinary tract
symptoms and quality of life in women with multiple sclerosis.
METHODS: Thirty-five female patients with multiple sclerosis were randomized into two groups: a treatment group
(n = 18) and a sham group (n = 17). The evaluation included use of the Overactive Bladder Questionnaire, Medical
Outcomes Study Short Form 36, International Consultation on Incontinence Questionnaire Short Form, and
Qualiveen questionnaire. The intervention was performed twice per week for 12 weeks in both groups. The
treatment group underwent pelvic floor muscle training with assistance from a vaginal perineometer and
instructions to practice the exercises daily at home. The sham group received a treatment consisting of introducing a
perineometer inside the vagina with no exercises required. Pre- and post-intervention data were recorded.
RESULTS: The evaluation results of the two groups were similar at baseline. At the end of the treatment, the
treatment group reported fewer storage and voiding symptoms than the sham group. Furthermore, the differences
found between the groups were significant improvements in the following scores in the treatment group:
Overactive Bladder Questionnaire, International Consultation on Incontinence Questionnaire Short Form, and the
General Quality of Life, and Specific Impact of Urinary Problems domains of the Qualiveen questionnaire.
CONCLUSIONS: The improvement of lower urinary tract symptoms had a positive effect on the quality of life of
women with multiple sclerosis who underwent pelvic floor muscle training, as the disease-specific of quality of life
questionnaires demonstrated. This study reinforces the importance of assessing quality of life to judge the
effectiveness of a treatment intervention.
KEYWORDS: Vaginal perineometer; Sham treatment; Quality of life questionnaires; Pelvic floor exercises;
Neurogenic bladder.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic neurological disease
involving the deterioration of the white matter pathways in
the brain and spinal cord. MS is generally described as
either relapsing-remitting (the most common presentation
form), characterized by episodes of neurological dysfunc-
tion followed by remissions, or as primary progressive,
where patients present a continuous and progressive
decline in their neurological function.1,2
Lower urinary tract symptoms (LUTS) are highly pre-
valent and affect approximately 50 to 90% of these patients
throughout the course of the disease.2-4 Most patients report
a combination of both storage and voiding symptoms5,6
caused by parasympathetic dysfunction due to brain and
spinal cord damage.7
There are several treatments for this condition, such as
anti-cholinergic drugs, botulinum toxin, electrical stimula-
tion, surgical intervention, and pelvic floor muscle training
(PFMT). PFMT was developed by Kegel in 1948 and was
primarily used for treatment of stress urinary incontinence
(SUI). Few studies have evaluated PFMT for the treatment
of patients with MS.3,8
These symptoms are not life-threatening, and, thus, are
often neglected by health professionals. However, bladder
dysfunction is responsible for a significant negative impact
on the quality of life (QoL) of affected patients.1,9
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Health care professionals recognizing the impact of
urinary disorders on QoL in patients with MS is essential
for enabling appropriate investigations and judging the
effectiveness of the treatment intervention.1,9,10
Thus, the aim of this study was to compare PFMT and a
sham procedure for the treatment of LUTS and their effects
on QoL. The effects of PFMT on disability were discussed in
another study.11
MATERIALS AND METHODS
We performed a prospective randomized controlled trial
at the Neurourology Clinic of the Universidade Estadual de
Campinas (UNICAMP), Campinas, Brazil. The study was
approved by the Institutional Ethics Committee (protocol
number 242/2006), and all of the subjects provided
informed consent.
The clinical history and a neurological examination,
including a Kurtzke’s Expanded Disability Status Scale
(EDSS) evaluation, were assessed for each patient. The EDSS
is a neurological scale that grades the level of disability in
MS with a score that ranges from 0 (normal neurological
findings) to 10 (death due to MS).12
A questionnaire containing items asking about the
presence (’’yes’’ or ‘‘no’’) of daytime urinary frequency
and urgency, urge incontinence, nocturnal enuresis, noc-
turia, hesitancy, a slow urine stream, and incomplete
emptying was provided to the patients.
The Overactive Bladder Questionnaire (OAB-V8)13 is a
self-administered questionnaire designed to rate how
disturbed patients are regarding four OAB symptoms:
urinary frequency, urgency, nocturia, and urge inconti-
nence. The patients respond to each item using a 6-point
Likert scale ranging from 0 (not at all) to 5 (a very great
deal). The subjects were considered to have a likely
diagnosis of LUTS if their total score was more than eight.
The OAB-V8 is a questionnaire that is commonly used to
assess overactive bladder symptoms, but it is also an
important tool for evaluating the patients’ self-perception
of the symptoms caused by lower urinary tract dysfunction.
The inclusion criteria were as follows: women with a
definitive diagnosis of MS14 with a stable disease over the
previous four months; a relapsing-remitting form of MS; 18
years of age or older; an EDSS score12 less than or equal to
6.5; the cognitive capacity to complete the assessment and
treatment protocol; reporting lower urinary tract symptoms
(nine or more positive responses on the OAB-V8 ques-
tionnaire). The exclusion criteria were as follows: preg-
nancy, previous vaginal prolapse surgery, stress urinary
incontinence surgery, Caesarean section or vaginal delivery
in the six months prior to enrollment, MS relapse during
treatment (defined as any change in symptoms according to
the EDSS evaluation), pelvic organ prolapse (detected
during the vaginal examination) of grade II or more,15
urinary tract infection (confirmed by lab tests), and a post-
menopausal status due to a reduction in muscle strength
after menopause.16
Volunteers taking anti-cholinergic or other medications
for the treatment of LUTS were permitted to participate if
they had been taking the medication for at least three
months prior to enrollment and if the dosage would not
change over the duration of their participation in the study.
Similarly, if any participant reported any worsening of
double or blurred vision, increased muscle weakness,
fatigue, or deterioration in coordination, he or she was re-
evaluated by the neurologist using the EDSS. If his or her
EDSS score increased by more than 0.5 relative to their
initial score, he or she was removed from the study.
All of the patients were blind to the randomization and
were randomly allocated to one of the following two groups
according to a computer-generated randomization list:
treatment (GI, n = 18) or sham (GII, n = 17). The patients
were evaluated before and after the intervention. All of the
assessments were performed by a physiotherapist who was
blinded to the patient group assignments. The patients were
unaware of which group they were participating in until the
end of the study. Two different informed consent proce-
dures were prepared explaining each treatment and
provided to the patients only after the randomization.
Patient QoL was assessed using the Medical Outcomes
Study Short Form 36 (SF-36) questionnaire,17 the
International Consultation on Incontinence Questionnaire
Short Form (ICIQ-SF)10 and the Qualiveen,9 a disease-
specific questionnaire.
The SF-36 is a generic questionnaire with 36 questions and
eight multi-item scales containing physical function (ten
items), social function (two items), mental health (five
items), role limitation due to physical problems (four items),
role limitation due to emotional problems (three items),
vitality (four items), bodily pain (two items), and general
health perceptions (five items). An additional one-item
measure of any self-evaluated change in health status is also
available. Each domain is coded, summed, and transformed
into a scale from 0 (worst) to 100 (best).
The ICIQ-SF is a brief and subjective questionnaire that is
used to assess the level and impact of urinary incontinence
in the patients’ lives; it is comprised of three questions that
target the daytime frequency, severity of incontinence, and
QoL impact of the incontinence along with an eight-item
scale assessing the possible causes or situations related to
the urinary incontinence. The final ICIQ-SF score is the sum
of the total scores, ranging from 0 to 21; the higher the score,
the greater the impact on QoL.
The Qualiveen is an extensive questionnaire specifically
developed for use with patients with urinary dysfunction
due to neurological disorders. It is divided into two major
sections: the Specific Impact of Urinary Problems on Quality
of Life (SIUP) and General Quality of Life (GQoL). The SIUP
section is split into four domains (inconvenience, restric-
tions, fears, and impact on daily life), with a total of 30
questions. Each answer has five quantified items using a
five-category ordinal Likert scale, with values ranging from
0 (no impact) to 4 (great negative impact). The average for
each domain is calculated and used to determine the final
SIUP score, which also ranges from 0 to 4, with 4 being the
greatest negative impact. The GQoL section has nine
questions, also using a five-category ordinal Likert scale,
with values ranging from -2 to +2 (very badly to very well,
respectively). The final general QoL value is calculated as
the average of the nine questions, also ranging from -2 to +2.
All of the questionnaires used in this study were
translated into and validated in Portuguese.9,10,13,17 The
questionnaires were filled out by the patients at the
physiotherapist’s office, but, if necessary, the assistance of
the blind (to group affiliation) physiotherapist, who
conducted the evaluations, was allowed.
Pelvic floor musculature was evaluated according to the
PERFECT scheme18 (explained as follows) by digital
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examination, which includes assessments of the following:
power (P), scored from 0 (no contraction) to 5 (contraction
against strong resistance) according to the modified Oxford
grading system; endurance (E), noted in seconds and
referring to the duration that a maximal contraction could
be held; repetitions (R), recorded from muscle exhaustion
and described as the number of times (at maximum 10) that
contraction could be repeated without losing both power
and endurance; the number of fast contractions (F) with
every contraction timed (ECT).
The interventions (treatment and sham) were performed
by a single physiotherapist for GI and GII over a period of
12 weeks, with the participants in both groups attending
twice per week for 30 minutes per session.
The GI patients underwent an intervention that consisted
of PFMT in the supine position with the assistance of a
perineometer (Perina, Quark, Sa˜o Paulo, Brazil). The
patients were instructed to practice the exercises learned
during the intervention at home three times daily, without
the assistance of any device and in various positions (such
as sitting and standing). They were also advised to integrate
the exercises into their daily activities. The regimen was
evaluated weekly according to a vaginal assessment using
the PERFECT scheme and by the physiotherapist respon-
sible for the treatment; the data were recorded by the blind
physiotherapist before and after the intervention. The
training focused on improving pelvic floor muscle aware-
ness and contraction strength, and the exercises were
individualized according to the degree of pelvic floor
weakness, the loss of proprioception and the patient’s
tolerance.
The GII patients received a sham procedure that solely
consisted of introducing a perineometer into the vagina. The
patients were asked to keep the device in place for 30
minutes, with no contraction required. No instructions
regarding performing the exercises at home were given.
The physiotherapist was present during all of the sham
procedures.
Statistical analysis was performed using the SAS
(Statistical Analysis System) system for Windows. The data
from nine patients were used to perform a pilot study, and
the desired sample size was determined using an SAS
program (fpower).
The sample size needed was calculated on the basis of the
pilot study, with four patients in GI and five patients in GII.
The evaluations chosen for this test were the following: pad
testing, bladder diary (number of pads) and the ICIQ-SF. By
setting the alpha at 5% and the power at 90%, the results of
the sample size calculation showed that 10 patients were
necessary for each group.
To compare the baseline measurements between the two
groups, a Mann-Whitney test was employed, and repeated-
measures ANOVA was used to compare the measurements
between groups. To compare proportions, we used the chi-
square or Fisher’s exact test. For all of the statistical tests, the
significance criterion of p,0.05 was used.
RESULTS
Between July 2007 and December 2008, a total of forty-two
patients consented, out of which thirty-five fulfilled the
inclusion criteria. The exclusions were resulted from the
following: the impossibility of attending the treatment twice
per week (six patients), a relapse of MS (three patients),
voluntary dropout (three patients), treatment denial (one
patient), and a urinary tract infection diagnosis before (one
patient) or during (one patient) the intervention. (Figure 1).
The patients who were excluded from the study but
wanted to continue the treatment were treated by the
physiotherapy staff.
The baseline demographic data and the initial assessment
are shown in Table 1. No statistical differences were found
between groups.
The numbers of patients in each group complaining about
storage and voiding symptoms before and after the
intervention, based on their initial clinical history, are
shown in Table 2.
After the treatment, no differences in the EDSS assess-
ment were found between the groups.
In contrast, there were significant differences in the OAB-
V8 assessment between the groups (p,0.0001) (Figure 2).
In the SF-36 assessment, no differences were found
between GI and GII.
Figure 1 - The excluded patients throughout the study.
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In the ICIQ-SF assessment, significant differences
(p= 0.0003) were found between the two groups (Figure 3).
In the Qualiveen questionnaire, the Specific Impact of
Urinary Problems on Quality of Life (SIUP) domain showed
significant differences (p= 0.0001) between the groups. In
the same manner, the General QoL domain of the same
questionnaire showed significant differences (p= 0.0443)
between GI and GII (Figure 4).
Compliance was based on the patients’ attendance at the
clinic sessions, and there was no difference in compliance
(p= 0.9622) between the patients in GI (mean+SD = 21.5+1.8)
vs. GII (mean+SD = 21.5+1.8) across the 24 sessions.
DISCUSSION
In the patients who were analyzed in this study, the
impairment measured by EDSS was unchanged.
Rehabilitation will not improve the neurological damage,
but it will certainly reduce the disability and help patients
face the disability with a better outlook.19,20
Both groups had the same visit schedule. Thus, the
observed improvement was not due to the relationship
between the health care professionals and their patients.
The OAB-V8 was very important for analyzing urinary
symptoms in these patients with MS. This questionnaire is
commonly used to assess overactive bladder symptoms, but
it was observed that it is an important tool for evaluating the
patients’ self-perception of LUTS.
Although movement disorders, depressive moods, and
fatigue affect the QoL of people with MS,19,21,22 urinary
problems also have a major impact on the health-related
QoL of these patients.1
The patients who underwent PFMT presented improve-
ment in their LUTS and QoL compared with the sham
group. It would seem reasonable to assume that a decrease
in LUTS would increase QoL. However, a randomized
controlled trial3 found encouraging results regarding the
treatment of LUTS but unclear results regarding any
improvement in QoL.
QoL should be evaluated using generic and disease-
specific21,10 instruments. The most commonly used instru-
ment to assess general QoL is the SF-36.5,20,22,23 In our study,
this questionnaire was not adequately sensitive to detect
Table 1 - The mean, standard deviation (SD) and p-value of the baseline, demographic data and the initial assessments
in the treatment (GI) and sham (GII) groups, as determined by the Mann-Whitney test.
Data GI GII p-value
Age in years (SD); range: 20-49 36.0 (7.2) 34.7 (8.8) 0.69
Body mass index (kg/m); range: 16.6-33.3 23.4 (3.1) 23.8 (3.6) 0.97
Parity; range: 0-3 1.3 (1.3) 1.1 (1.2) 0.83
EDSS; range: 1.5 - 6.5 3.4 (1.5) 3.3 (1.5) 0.77
Duration of urinary disorders (months); range: 6- 132 36.5 (37.4) 31.5 (20.8) 0.93
Duration of MS since the onset of the disease (years); range: 3 - 20 9.1 (5.8) 6.8 (3.5) 0.39
OAB-V8; range: 10 - 40 23.8 (8.5) 27.1 (10.1) 0.38
ICIQ-SF; range: 0 - 18 11.4 (5.5) 11.1 (5.4) 0.89
Qualiveen – SIUP; range: 0.3 - 3 1.7 (0.6) 1.8 (0.9) 0.72
Qualiveen – GQoL; range: - 1.2 - 1.6 0.2 (0.8) 0.3 (1.0) 0.80
SF-36 – PF; range: 0 - 100 39.2 (19.7) 33.6 (30.8) 0.30
SF-36 – SF; range: 12.5 - 75 46.2 (21.3) 41.1 (14.2) 0.59
SF-36 – MH; range: 32 - 76 54.8 (11.7) 53.4(14.5) 1.00
SF-36 – RP; range: 0 - 100 38.5 (42.8) 37.5 (40.1) 1.00
SF-36 – RE; range: 0 - 100 61.5 (40.5) 54.8 (46.4) 0.64
SF-36 – VT; range: 25 - 80 56.9 (10.3) 51.8 (13.8) 0.48
SF-36 – BP; range: 0 - 100 44.4 (24.0) 46.0 (26.1) 0.63
SF-36 – GH; range: 35 - 90 61.5 (15.3) 52.5 (12.4) 0.12
SIUP, specific impact of urinary problems on quality of life; GQoL, general quality of life; PF, physical function; SF, social function; MH, mental health; RP,
role limitation due to physical problems; RE, role limitation due to emotional problems; VT, vitality; BP, bodily pain; GH, general health perceptions.
Table 2 - The number of patients complaining about
storage and voiding symptoms before and after the
intervention in the treatment (GI) and sham (GII) groups.
GI GII
SYMPTOMS Baseline Final Baseline Final p-value
Frequency 13 4 14 14 ,0.0001
Urgency 13 4 14 13 0.0013
Urge urinary
incontinence
12 4 13 13 0.0013
Nocturnal enuresis 8 2 9 10 0.0034
Nocturia 12 2 12 11 0.0010
Hesitancy 10 3 8 9 0.0313
Slow stream 8 5 6 6 0.8163
Incomplete emptying 8 3 7 7 0.2365
Figure 2 - The mean and standard deviation of the OAB-V8
before and after the intervention in treatment (GI) and sham
(GII) groups. Mean: 23.84 initial and 5.92 final in GI; 27.14 initial
and 28.21 final in GII (p,0.0001).
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any improvement in QoL, which is predictable given that
this is a general questionnaire and does not specifically
measure the impact of urinary urgency, frequency, nocturia,
and incontinence on QoL.
Studies have shown that MS patients have a worse QoL
compared with non-MS populations,24 which explains the
importance of identifying specific problems that have
negative impacts on QoL. The Qualiveen questionnaire
showed that PFMT improves LUTS and contributes to both
an improved General Quality of Life domain and a Specific
Impact of Urinary Problems on Quality of Life domain.
The findings of this study show that, although it is
subjective, the assessment of QoL provides important
additional information about the effects of the proposed
treatment, the measure of the rehabilitation outcomes and
the patients evaluation of their own health. This information
will help health professionals to choose the best treatment to
obtain the most improvement.
CONCLUSION
The improvement of LUTS had a positive effect on QoL in
women with MS who underwent PFMT compared with a
sham group. This study reinforces the importance of
assessing QoL to judge the effectiveness of a treatment
intervention. Furthermore, a disease-specific QoL tool should
be used to identify the specific problems that contribute to
negative impacts on QoL in patients with MS.
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